N'-hydroxy-2-pentyl-N-phenylpropanediamide | 56384-28-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-hydroxy-2-pentyl-N-phenylpropanediamide
• CAS: 56384-28-2
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: YOEVRQFFYZVWBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  pentylmalonic acid monoethyl ester 在 hydroxide 、 羟胺 、 N,N'-二环己基碳二亚胺 作用下， 生成 N'-hydroxy-2-pentyl-N-phenylpropanediamide
  参考文献：
  名称：

  有关抗生素肌动蛋白的研究。第六部分 通过二环己基碳二亚胺偶联反应合成肌动蛋白的结构类似物

  摘要：

  已经研究了氨基酰胺（I）与二羧酸的单烷基酯（V）的偶联，作为特异性合成肌动蛋白（XVII）的结构类似物（II）和（III）的途径。已经开发了用于合成异构体（X）和（XI）的方法，但是通过使用二环己基碳二亚胺将它们与氨基酰胺（I）偶联的方法不是特定的。

  DOI：

  10.1039/p19750000848

文献信息

• Methods of inducing terminal differentiation
  申请人：Merck HDAC Research, LLC

  公开号：EP2082737A2

  公开（公告）日：2009-07-29

  The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

  本发明提供了通过服用包含强效 HDAC 抑制剂的药物组合物，选择性地诱导肿瘤细胞的终末分化、细胞生长停滞和/或凋亡，和/或抑制组蛋白去乙酰化酶（HDAC）的方法。本发明药物组合物中活性化合物的口服生物利用度出奇地高。此外，本发明的药物组合物出人意料地能在较长时间内产生较高的、治疗有效的活性化合物血药浓度。本发明进一步提供了这些药物组合物的安全、每日给药方案，该方案易于遵循，并能在体内产生治疗有效量的 HDAC 抑制剂。
• Use of SAHA for treating mesothelioma
  申请人：Merck HDAC Research, LLC

  公开号：EP2201947A2

  公开（公告）日：2010-06-30

  The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More specifically, the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

  本发明涉及治疗癌症的方法，例如间皮瘤或淋巴瘤。更具体地说，本发明涉及治疗间皮瘤或弥漫性大B细胞淋巴瘤（DLBCL）的方法，方法是服用包含HDAC抑制剂的药物组合物，例如亚伯酰苯胺羟肟酸（SAHA）。药物组合物的口服制剂具有良好的药代动力学特征，如生物利用度高，并能在较长时间内令人惊讶地产生较高的活性化合物血药浓度。本发明进一步提供了这些药物组合物安全的每日给药方案，该方案易于遵循，并能在体内产生治疗有效量的 HDAC 抑制剂。
• [EN] METHODS OF INDUCING TERMINAL DIFFERENTIATION<br/>[FR] PROCEDES D'INDUCTION DE DIFFERENCIATION TERMINALE
  申请人：ATON PHARMA INC

  公开号：WO2003075839A2

  公开（公告）日：2003-09-18

  The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
• [EN] COMBINATION METHODS OF TREATING CANCER<br/>[FR] METHODES COMBINEES DE TRAITEMENT DU CANCER
  申请人：ATON PHARMA INC

  公开号：WO2005023179A2

  公开（公告）日：2005-03-17

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
• [EN] COMBINATION METHODS OF SAHA AND TARGRETIN FOR TREATING CANCER<br/>[FR] METHODES DE TRAITEMENT DU CANCER COMBINANT SAHA ET TARGRETIN
  申请人：MERCK & CO INC

  公开号：WO2007022408A2

  公开（公告）日：2007-02-22

  [EN] The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of SAHA or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of Targretin. The SAHA and Targretin may be administered to comprise therapeutically effective amounts.
  [FR] L'invention concerne une méthode de traitement du cancer chez un sujet nécessitant un tel traitement, qui consiste à administrer audit sujet une première quantité de SAHA (acide hydroxamique suberoylanilide) ou d'un sel ou d'un hydrate pharmaceutiquement acceptables de ce composé, et une deuxième quantité de Targretin. Le SAHA et le Targretin sont administrés en quantités thérapeutiquement efficaces.